I
I. Buijt
Researcher at Erasmus University Rotterdam
Publications - 10
Citations - 404
I. Buijt is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: CHOP & Transplantation. The author has an hindex of 7, co-authored 10 publications receiving 384 citations.
Papers
More filters
Journal ArticleDOI
CHOP Compared With CHOP Plus Granulocyte Colony-Stimulating Factor in Elderly Patients With Aggressive Non-Hodgkin’s Lymphoma
J.K. Doorduijn,B. van der Holt,G. W. van Imhoff,K. G. van der Hem,M. H. H. Kramer,M. H. J. Van Oers,Gert J. Ossenkoppele,M. R. Schaafsma,L. F. Verdonck,Gregor Verhoef,Monique Steijaert,I. Buijt,C.A. Uyl-de Groot,M van Agthoven,Andries H. Mulder,Pieter Sonneveld +15 more
TL;DR: In this article, the relative dose-intensity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy was investigated in elderly patients with aggressive non-Hodgkin's lymphoma (NHL).
Journal ArticleDOI
Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy.
Jeanette K. Doorduijn,I. Buijt,Bronno van der Holt,Monique Steijaert,Carin A. Uyl-de Groot,Pieter Sonneveld +5 more
TL;DR: Soon after completion of therapy, the QoL of the lower aaPI group returned to pretreatment levels or better, while patients with higher aa PI showed a significant improvement in QoD compared to baseline levels.
Journal ArticleDOI
A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma: a prospective randomised phase III study
M van Agthoven,C.M. Segeren,I. Buijt,C.A. Uyl-de Groot,B. van der Holt,Henk M. Lokhorst,Pieter Sonneveld +6 more
TL;DR: Cost-effectiveness of myeloma therapy after 3 years of follow up seems not to be favoured by myeloablative treatment with autologous stem-cell rescue, and intensive chemotherapy is regarded as standard therapy for younger patients with previously untreated MM.
Journal ArticleDOI
Health related quality of life in patients with multiple myeloma undergoing a double transplantation.
C.A. Uyl-de Groot,I. Buijt,I. J. M. Gloudemans,Gert J. Ossenkoppele,H. P. Berg,Peter C. Huijgens +5 more
TL;DR: Overall, patients’ functioning improved during treatment and follow‐up, with significant decreases shortly following PSCT, and the evaluation of quality of life invites further exploration of double transplantations in multiple myeloma.
Journal ArticleDOI
Economics and health-related quality of life in antiemetic therapy: recommendations for trial design
TL;DR: It is the combination of clinical outcomes, costs and health-related quality of life, which will allow treating physicians to comprehensively assess the relative value of antiemetic therapies and to provide the most cost-effective therapy for their patients.